<DOC>
	<DOCNO>NCT02960594</DOCNO>
	<brief_summary>This Phase I , open label study evaluate safety , tolerability , immunogenicity INO-1400 alone combination INO-9012 , deliver electroporation subject high-risk solid tumor cancer evidence disease surgery standard therapy . Subjects enrol one six treatment arm . Subjects assess accord standard care . Restaging image study perform assess disease relapse per NCCN guideline . RECIST use validate finding case relapse .</brief_summary>
	<brief_title>hTERT Immunotherapy Alone Combination With IL-12 DNA Followed Electroporation Adults With Solid Tumors High Risk Relapse</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>1 . Signed date write IRB approve informed consent ; 2 . Males female age â‰¥18 year ; 3 . Subjects breast , lung pancreatic carcinoma high risk relapse post definitive therapy least 4 24 week completion definitive therapy time sign informed consent describe indication : Breast carcinoma : Lung carcinoma : Pancreatic carcinoma : Head neck squamous cell carcinoma : Ovarian cancer : Colorectal cancer Gastric esophageal cancer Hepatocellular carcinoma 1 . Previous treatment wth TERT IL12 contain therapy , DNA immunotherapy ; 2 . Any concurrent condition require continue anticipate use systemic steroid ( exclude nonsystemic inhale , topical skin and/or eye dropcontaining corticosteroid ) immunosuppressive therapy ( excludes low dose methotrexate ) . All systemic corticosteroid must discontinue least 4 week prior first Study Treatment ; 3 . Administration vaccine within 4 week first study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Human Telomerase Reverse Transcriptase ( hTERT )</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Pancreatic Neoplasms</keyword>
	<keyword>High Risk Relapse</keyword>
	<keyword>Post Definitive Surgery</keyword>
	<keyword>Post Adjuvant Therapy</keyword>
	<keyword>No Evidence Disease</keyword>
</DOC>